Insmed reported $53.11M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
DBV Technologies DBVT:US 2.55M 386K
Acelrx Pharmaceuticals ACRX:US $ 0.44M 0.44M
Alimera Sciences ALIM:US $ 11.9M 2.06M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Cytokinetics CYTK:US $ 1.15M 54.45M
Dynavax Technologies DVAX:US $ 113.99M 81.08M
Gilead Sciences GILD:US $ 6590M 654M
Heron Therapeutics HRTX:US $ 23.46M 2.8M
Insmed INSM:US $ 53.11M 3.02M
Mirati Therapeutics MRTX:US $ 0.71M 0.41M
Novartis NVS:US $ 12814M 708M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Sarepta Therapeutics SRPT:US $ 210.83M 9.37M
Seattle Genetics SGEN:US $ 426.46M 3.39M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M